hydroxychloroquine has been researched along with Alloxan Diabetes in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is a widely used antimalarial and anti-inflammatory drug and its hyperglycemia-controlling effect in diabetic patients is also under investigation." | 3.01 | Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19? ( Das, A; Koka, S; Kukreja, RC; Samidurai, A; Wang, R; Xi, L, 2023) |
| " In conclusion, the CQ dosage and regimen used to treat COVID-19 induced adverse effects in diabetic rats, suggesting the need to reevaluate the effective dose of CQ in humans." | 1.72 | Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19. ( Gao, X; Guo, D; Ji, H; Jiang, S; Jing, X; Peng, L; Qiu, Y; Wang, J; Wu, W; Zheng, Y, 2022) |
| "The pharmacokinetic studies were carried out following administration of 40 mg/kg of racemic HCQ to diabetic, insulin-treated diabetic, adjuvant arthritic and control rats." | 1.30 | Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. ( Emami, J; Jamali, F; Pasutto, FM, 1998) |
| "To study the effect of hydroxychloroquine (HCQ) on glucose and insulin homeostasis, healthy rats were dosed with 160 mg x kg (-1) x day(-1) of HCQ orally, and streptozocin-induced diabetic rats received 80, 120, and 160 mg x kg(-1) x day(-1) of HCQ, while controls received normal saline." | 1.30 | Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. ( Emami, J; Gerstein, HC; Jamali, F; Pasutto, FM, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, X | 1 |
| Jing, X | 1 |
| Wang, J | 1 |
| Zheng, Y | 1 |
| Qiu, Y | 1 |
| Ji, H | 1 |
| Peng, L | 1 |
| Jiang, S | 1 |
| Wu, W | 1 |
| Guo, D | 1 |
| Kukreja, RC | 1 |
| Wang, R | 1 |
| Koka, S | 1 |
| Das, A | 1 |
| Samidurai, A | 1 |
| Xi, L | 1 |
| Abdel-Hamid, AA | 1 |
| El-Firgany, Ael-D | 1 |
| Emami, J | 3 |
| Pasutto, FM | 3 |
| Jamali, F | 3 |
| Mercer, JR | 1 |
| Gerstein, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hydroxychloroquine to Improve Insulin Sensitivity in Rheumatoid Arthritis[NCT01132118] | Phase 3 | 30 participants (Actual) | Interventional | 2010-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 58.1 | 59.4 | 1.3 |
| Placebo | 58.1 | 60.3 | 2.2 |
HOMA-B = (360 x Insulin)/(Glucose - 63) (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mIU x dL)/(L x mg) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 116.5 | 110.8 | -5.8 |
| Placebo | 116.5 | 109.7 | -6.8 |
"We will examine the effect of HCQ on HOMA-IR during the active treatment phase compared with placebo phase.~HOMA-IR = (Glucose x insulin)/405" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (mg x mIU)/(dL*L) (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 2.0 | 1.7 | -0.3 |
| Placebo | 2.0 | 1.6 | -0.42 |
"We will examine the effect of HCQ on the Matsuda Insulin Sensitivity Index (ISI) during the active treatment phase compared with placebo phase.~ISI is based on insulin and glucose levels in a fasting state during an oral glucose tolerance test (OGTT) and is calculated as follows:~ISI (Matsuda) = 10000/√ G0 X I0 X Gmean X Imean~G0 - fasting plasma glucose (mg/dL) I0 - fasting plasma insulin (mIU/L) Gmean - mean plasma glucose during OGTT (mg/dL) Imean - mean plasma insulin during OGTT (mIU/L)" (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | (dL x L)/(mg x mIU) (Mean) | ||
|---|---|---|---|
| Baseline | Period Value | Change | |
| Hydroxychloroquine | 7.7 | 8.1 | 0.4 |
| Placebo | 7.7 | 7.8 | 0.14 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 114.1 | 101.7 | -12.4 |
| Placebo | 114.1 | 109.9 | -4.2 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 192.4 | 179.7 | -12.7 |
| Placebo | 192.4 | 189.4 | -3.0 |
mg/dL (NCT01132118)
Timeframe: Baseline and Week 8
| Intervention | mg/dL (Mean) | ||
|---|---|---|---|
| Baseline | Period | Change | |
| Hydroxychloroquine | 100.6 | 92.4 | -8.2 |
| Placebo | 100.6 | 95.6 | -5.0 |
1 review available for hydroxychloroquine and Alloxan Diabetes
| Article | Year |
|---|---|
Treating diabetes with combination of phosphodiesterase 5 inhibitors and hydroxychloroquine-a possible prevention strategy for COVID-19?
Topics: Animals; COVID-19; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2023 |
5 other studies available for hydroxychloroquine and Alloxan Diabetes
| Article | Year |
|---|---|
Safety considerations of chloroquine in the treatment of patients with diabetes and COVID-19.
Topics: Animals; Chloroquine; COVID-19 Drug Treatment; Diabetes Mellitus, Experimental; Diabetes Mellitus, T | 2022 |
Hydroxychloroquine hindering of diabetic isletopathy carries its signature on the inflammatory cytokines.
Topics: Animals; Biomarkers; Caspase 3; Cytokines; Diabetes Mellitus, Experimental; Enzyme-Linked Immunosorb | 2016 |
Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats.
Topics: Animals; Antirheumatic Agents; Arthritis, Experimental; Diabetes Mellitus, Experimental; Hydroxychlo | 1998 |
Inhibition of insulin metabolism by hydroxychloroquine and its enantiomers in cytosolic fraction of liver homogenates from healthy and diabetic rats.
Topics: Animals; Cytosol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Enzyme Inhibitors; Hyd | 1999 |
Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Hydroxych | 1999 |